Eli Lilly Surges 5.4% Pre-Market on Massive Q1 Beat and Guidance Hike

GLP-1 Dominance Drives Record Results

Eli Lilly (LLY) is sharply outperforming the broader market in early trading today, as investors react to a first-quarter performance that underscores the company's leadership in the high-growth obesity and diabetes markets. While the S&P 500 (SPY) remained flat in the pre-market session, Lilly shares climbed 5.45% on volume of 93.3K shares, reflecting intense institutional interest ahead of the opening bell.

The primary catalyst is a massive double-beat on the top and bottom lines. Lilly reported Q1 revenue of $19.8 billion, a 56% increase year-over-year, which blew past the analyst consensus of $17.6 billion. The earnings performance was even more pronounced; the company posted non-GAAP diluted EPS of $8.55, far exceeding the $6.89 to $7.06 range expected by Wall Street.

Mounjaro and Zepbound Fuel Growth

The results were powered by the continued meteoric rise of Lilly’s weight-loss and diabetes treatments. Mounjaro generated $8.66 billion in quarterly revenue, a staggering 125% increase from the prior year. Zepbound followed suit, contributing $4.16 billion in revenue, up 80% year-over-year.

Management noted that while realized prices for these drugs have seen some downward pressure due to expanded coverage and competition, the sheer volume of prescriptions has more than compensated for the price erosion. Volume growth for the quarter reached 65%, signaling that the market for GLP-1 therapies is still expanding rapidly.

Guidance Hike and New Drug Approval

Beyond the Q1 numbers, Lilly provided a significant boost to its full-year 2026 guidance, a move that typically triggers sharp upward revisions in analyst price targets. The company now expects annual revenue between $82.0 billion and $85.0 billion, up from its previous range of $80.0 billion to $83.0 billion. It also lifted its non-GAAP EPS forecast to a range of $35.50 to $37.00, well above the prior consensus of $34.53.

Adding to the bullish sentiment was the announcement of the U.S. FDA approval of Foundayo (orforglipron). CEO David Ricks highlighted Foundayo as a "key milestone," noting it is the only approved GLP-1 pill that can be taken at any time of day without food or water restrictions. This oral option is expected to significantly broaden the patient base for obesity treatments, providing a competitive edge over injectable alternatives.

Forward Outlook

Lilly's pre-market surge suggests the stock is poised to reclaim its momentum as the premier growth play in the large-cap pharmaceutical sector. With the company also announcing four strategic acquisitions in the quarter—including Kelonia and Ajax Therapeutics—Lilly is aggressively diversifying its pipeline into CAR-T cell therapies and immunology. Investors will likely focus on the 10:00 AM ET conference call for further details on the Foundayo rollout and supply chain capacity for its blockbuster injectables.